With the advent of 12 week therapies for chronic HCV with high efficacy, the impetus for early identification the acute phase of infection is no longer based on enhanced treatment efficacy. Instead, the rationale for identifying infection is to provide important counseling and care aimed at enhancing personal health and preventing secondary cases. Ongoing trials will determine whether shorter and/or less intensive courses of antivirals during the acute phase of infection will result in excellent cure rates and preserve immune responses that may be important in the prevention of reinfection after viral clearance.